Insight Molecular Diagnostics, Inc. (IMDX)
2.49
+0.03
(+1.22%)
USD |
NASDAQ |
Nov 06, 16:00
2.50
+0.01
(+0.40%)
After-Hours: 20:00
Insight Molecular Diagnostics Max Drawdown (5Y) : 98.49% for Oct. 31, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| October 31, 2026 | 98.49% |
| September 30, 2026 | 98.49% |
| August 31, 2026 | 98.49% |
| July 31, 2026 | 98.49% |
| June 30, 2026 | 98.49% |
| May 31, 2026 | 98.49% |
| April 30, 2026 | 98.49% |
| March 31, 2026 | 98.49% |
| February 28, 2026 | 98.49% |
| January 31, 2026 | 98.49% |
| December 31, 2025 | 98.49% |
| November 30, 2025 | 98.49% |
| October 31, 2025 | 98.49% |
| September 30, 2025 | 98.49% |
| August 31, 2025 | 98.49% |
| July 31, 2025 | 98.49% |
| June 30, 2025 | 98.49% |
| May 31, 2025 | 98.49% |
| April 30, 2025 | 98.49% |
| March 31, 2025 | 98.49% |
| February 28, 2025 | 98.49% |
| January 31, 2025 | 98.49% |
| December 31, 2024 | 98.40% |
| November 30, 2024 | 98.40% |
| October 31, 2024 | 98.40% |
| Date | Value |
|---|---|
| September 30, 2024 | 98.40% |
| August 31, 2024 | 98.40% |
| July 31, 2024 | 98.40% |
| June 30, 2024 | 98.40% |
| May 31, 2024 | 98.40% |
| April 30, 2024 | 98.40% |
| March 31, 2024 | 98.40% |
| February 29, 2024 | 98.40% |
| January 31, 2024 | 98.40% |
| December 31, 2023 | 98.40% |
| November 30, 2023 | 98.40% |
| October 31, 2023 | 98.25% |
| September 30, 2023 | 97.60% |
| August 31, 2023 | 97.45% |
| July 31, 2023 | 96.96% |
| June 30, 2023 | 96.92% |
| May 31, 2023 | 96.92% |
| April 30, 2023 | 96.92% |
| March 31, 2023 | 96.92% |
| February 28, 2023 | 96.09% |
| January 31, 2023 | 96.09% |
| December 31, 2022 | 96.09% |
| November 30, 2022 | 94.04% |
| October 31, 2022 | 90.14% |
| September 30, 2022 | 90.14% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Perspective Therapeutics, Inc. | 93.75% |
| Agenus, Inc. | 98.84% |
| Amgen, Inc. | 24.86% |
| Anika Therapeutics, Inc. | 83.15% |
| BioCryst Pharmaceuticals, Inc. | 79.10% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -65.64 |
| Beta (5Y) | 1.900 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 83.06% |
| Historical Sharpe Ratio (5Y) | -0.6025 |
| Historical Sortino (5Y) | -1.430 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 30.38% |